Susten 30 - Tablet - (30mg)

Dapoxetine Hydrochloride is indicated for the treatment of premature ejaculation (PE) in men 18 to 64 years of age, who have one or all of the following:

Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and before the patient wishes.

Marked personal distress or interpersonal difficulty as a consequence of PE.

Poor control over ejaculation.

Patients with known hypersensitivity to Dapoxetine Hydrochloride.

Patients with significant pathological cardiac conditions (such as heart failure (NYHA class ll-IV), conduction abnormalities (second- or third-degree AV block or sick sinus syndrome) not treated with a permanent pacemaker, significant ischemic heart disease or significant valvular disease.

Concomitant treatment with monoamine oxidase inhibitors (MAOIs), thioridazine, or within 14 days of discontinuing treatment with MAOIs, thioridazine. Similarly, MAOIs, thioridazine should not be administered within 7 days after Dapoxetine has been discontinued.

Concomitant treatment with serotonin reuptake inhibitors [selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs)] or other medicinal/herbal products with serotonergic effects or within 14 days of discontinuing treatment with these medicinal/herbal products.

The most common effects when taking Dapoxetine Hydrochloride are nausea, dizziness, dry mouth, headache, diarrhea, and insomnia. Discontinuation due to adverse effects is dose related. The rate of discontinuation is 0.3%, 1.7%, and 5.3% of 1067 studied subjects with placebo, Dapoxetine Hydrochloride 30 mg, and Dapoxetine Hydrochloride 60 mg respectively. Unlike others SSRIs used to treat depression, which have been associated with high incidences of sexual dysfunction, Dapoxetine Hydrochloride is associated with low rates of sexual dysfunction. Taken as needed, Dapoxetine Hydrochloride has very mild adverse effects on loss of libido (<1%) and ED (<4%).